Next-generation sequencing of circulating tumor DNA can optimize second-line treatment in RAS wild-type metastatic colorectal cancer after progression on anti-EGFR therapy : time to rethink our approach

Mauri, Davide and Kamposioras, Konstantinos and Matthaios, Dimitrios and Tolia, Maria and Nixon, Ioanna and Dambrosio, Mario and Zarkavelis, Georgios and Papadimitriou, Konstantinos and Petricevic, Branka and Kountourakis, Pantelis and Kopecky, Jindrich and Kuhar, Cvetka Grašič and Popovic, Lazar and Chilingirova, Nataliya P. and De Mello, Ramon Andrade and Plavetić, Natalija Dedić and Katsanos, Konstantinos and Mostert, Bianca and Alongi, Filippo and De Bari, Berardino and Corradini, Stefanie and Kampletsas, Eleytherios and Gazouli, Ioanna and Gkoura, Stefania and Amylidi, Anna Lea and Valachis, Antonios (2022) Next-generation sequencing of circulating tumor DNA can optimize second-line treatment in RAS wild-type metastatic colorectal cancer after progression on anti-EGFR therapy : time to rethink our approach. Oncology Research and Treatment, 45 (4). pp. 216-221. ISSN 2296-5262 (https://doi.org/10.1159/000521845)

[thumbnail of Mauri-etal-ORT-2022-Next-generation-sequencing-of-circulating-tumor-DNA-can-optimize-second-line-treatment-in-RAS-wild-type-metastatic-colorectal-cancer]
Preview
 Text. Filename: Mauri_etal_ORT_2022_Next_generation_sequencing_of_circulating_tumor_DNA_can_optimize_second_line_treatment_in_RAS_wild_type_metastatic_colorectal_cancer.pdf
Accepted Author Manuscript
License: Strathprints license 1.0
Download (718kB)| Preview

Abstract

Background: Management of Ras wild-type colorectal cancer (CRC) patients upon disease progression after the successful use of targeted treatment with anti-EGFR monoclonal antibodies and backbone chemotherapy remains a clinical challenge. Summary: Development of treatment resistance with prevalence of preexisting RAS mutated clones, RAS mutation conversion, truncation of extracellular receptor domains as well as HER2 and MET amplification are molecular events that can be difficult to follow without the use of sophisticated laboratory techniques. The clinical hurdle of re-biopsy and tumor heterogeneity can be overcome by the implementation of next-generation sequencing (NGS) to analyze circulating tumor DNA (ctDNA) and identify druggable mutations or recovery of RAS-wildness. In this opinion paper, we summarize with critical thinking the clinical approach to be followed after the failure of first-line treatment in Ras wild-type CRC tumors with the use of NGS. Rechallenge with anti-EGFR inhibitors, in case of persistent or recovery of RAS-wildness, and targeted approach of specific mutations (BRAF inhibitors), amplifications (anti-Her2 treatment), or fusion proteins (NTRK inhibitors) can by guided by the use of NGS. The use of NGS platforms for serial analysis of ctDNA is an important step to better understand the molecular landscape of metastatic CRC and guide clinical decisions. Key Messages: NGS should be considered a mainstay in clinical practice for the management of CRC patients and health authorities should consider reimbursing its use in the appropriate clinical settings.

ORCID iDs

Mauri, Davide, Kamposioras, Konstantinos, Matthaios, Dimitrios, Tolia, Maria, Nixon, Ioanna ORCID logoORCID: https://orcid.org/0000-0003-3223-0700, Dambrosio, Mario, Zarkavelis, Georgios, Papadimitriou, Konstantinos, Petricevic, Branka, Kountourakis, Pantelis, Kopecky, Jindrich, Kuhar, Cvetka Grašič, Popovic, Lazar, Chilingirova, Nataliya P., De Mello, Ramon Andrade, Plavetić, Natalija Dedić, Katsanos, Konstantinos, Mostert, Bianca, Alongi, Filippo, De Bari, Berardino, Corradini, Stefanie, Kampletsas, Eleytherios, Gazouli, Ioanna, Gkoura, Stefania, Amylidi, Anna Lea and Valachis, Antonios;
CORE (COnnecting REpositories)